Gastrointestinal Neoplasms  >>  Imjudo (tremelimumab)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Imjudo (tremelimumab) / AstraZeneca, Pfizer
NCT00556023: A Phase 1 Study Testing CP-675,206 In Combination With Gemcitabine In Patients With Previously Untreated, Advanced Pancreatic Cancer

Checkmark P1 data
May 2011 - May 2011: P1 data
Completed
1
37
Canada, Europe
CP-675,206 and gemcitabine
AstraZeneca
Pancreatic Cancer
08/11
08/11
NCT02868632: Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer

Withdrawn
1
0
US
MEDI4736, Durvalumab, Tremelimumab, CP-675,206, Stereotactic Body Radiation Therapy (SBRT)
NYU Langone Health, AstraZeneca
Pancreatic Cancer
03/19
03/19

Download Options